Nevisense Platform

Discover the power of early skin diagnostics
Nevisense is SciBase’s flagship platform for advanced skin diagnostics and research. Combining Electrical Impedance Spectroscopy (EIS) with AI-powered analysis, Nevisense enables clinicians and researchers to uncover what’s happening below the surface of the skin – delivering objective insights that support early detection, accurate assessment and better outcomes.

Nevisense measures the skin's electrical properties using EIS. A safe electrical signal is applied via a single-use electrode, capturing the skin’s response across different depths and frequencies. These data points are then analyzed using embedded AI algorithms to identify deviations in cellular structure and orientation – helping detect skin cancer or assess skin barrier function. This non-invasive method provides objective support to clinical decisions, increasing diagnostic confidence and reducing unnecessary procedures.

Applications: From cancer detection to skin barrier research

Nevisense is CE-marked and FDA-approved for clinical use in melanoma detection, and also supports identification of keratinocyte cancers like BCC and SCC. Beyond cancer, it is increasingly used in dermatological research:

Melanoma detection: High sensitivity tool to differentiate between benign and malignant lesions.
Non-melanoma skin cancer: Supports detection of keratinocyte cancers.
Skin barrier assessment: Valuable for atopic dermatitis, eczema and other skin conditions.
Cosmetic testing: Quantify effects of skincare products on the skin barrier.

Built for the clinic: Fast, safe, point-of-care ready

Nevisense is designed for use in everyday clinical settings. The measurement process takes just minutes, requires minimal training, and delivers instant results on screen – helping guide decisions in real time. In research, the data can be exported for deeper analysis, documentation or longitudinal tracking. With a compact form factor, portable probe and easy-to-use interface, Nevisense integrates smoothly into clinical practice and research environments alike.

Reduces the risk of missing melanomas
Sensitivity of 97%
Studies show a 14% reduction in missed melanomas

Increases correct biopsy decisions
Proven to improve clinicians’ biopsy decisions
Rule out melanoma with 99% accuracy (NPV)

Clinically and scientifically proven
CE marked (MDR) and FDA-approved device
Proven in the largest clinical study of its kind

Scientifically validated, globally trusted

Nevisense is backed by over three decades of research and a large amount of scientific publications. With 300,000+ patients evaluated worldwide and more than 500 clinics using Nevisense for skin cancer detection, it is a trusted tool for dermatologists, academic researchers and life science companies.

Clinical trials have shown that Nevisense improves diagnostic performance when used alongside traditional examination methods, supporting better outcomes for patients and clinicians.